Patients who received ipilimumab plus nivolumab were more likely to experience a headache at time of hypophysitis diagnosis compared to those treated with anti-PD-(L)1 monotherapy (47% vs. 17%, p=0.05), but there were no significant differences in frequency of nausea and/or vomiting, hypotension, or fatigue between the groups. The gene discussed is CD274; the disease is hypophysitis.